AzTrials
AzTrials

Cow Milk Protein AllergyNCT07242950

Effect of Elimination Diet on Intestinal Mucus Barrier in Infants With Cow's Milk Protein Allergy

An observational study of Cow Milk Protein Allergy and Mucin, run by Baskent University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this observational study is to learn about the effects of cow's milk protein elimination diets on breastfed infants under 26 weeks of age with newly diagnosed non-IgE-mediated CMPA. Read more about this study

Who is it for?
Ages 1 week to 26 weeksHealthy volunteers can take part
Conditions the study is for
Cow Milk Protein Allergy, Mucin, Immunoglobulin A
How many people
34 participants
Where
1 siteTurkey (Türkiye)
Study dates
4 Sep 2023to 30 Aug 2024
How long will I take part?
3 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 week to 26 weeks
  • All sexes
  • Healthy volunteers accepted
  • Child

Study population: The study included breastfed babies under 26 weeks of age who were diagnosed with new non-IgE-mediated CMPA by an allergist, had an elimination diet, and applied to two hospitals designated in Türkiye. Infants and their mothers without allergies or atopic diseases, similar in age and gender, were in the control group.

Who may be able to join

  • Diagnosed with non-IgE-mediated ARI during the study period,
  • Aged less than 26 weeks at the beginning of the study,
  • Still breastfeeding,
  • Gestational age between 37 and 42 weeks,
  • Single birth,
  • Birth weight ≥ 2500 g and ≤ 4500 g, and their mothers.
Show all 17Show fewer
  • The exclusion criteria for the case group are as follows:
  • those with a diagnosed chronic or systemic disease, those with neonatal disease or congenital malformation, those who have had an infection or illness requiring hospitalisation during the study period, infants who have never been breastfed and their mothers.
  • Age less than 26 weeks at the beginning of the study,
  • No allergy to food or medication,
  • No diagnosis of an atopic disease,
  • Still breastfeeding,
  • Gestational age between 37 and 42 weeks,
  • Single birth,
  • Infants with birth weight ≥ 2500 g and ≤ 4500 g and their mothers.
  • The exclusion criteria for the control group are as follows:
  • Those with a diagnosed allergy or atopic disease, those with a diagnosed known chronic or systemic disease, those with neonatal disease or congenital malformations, those who have experienced an infection or illness requiring hospitalisation during the study period, infants who have never received breast milk and their mothers.

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Baskent University

    Ankara, Etimesgut, 06790

Other trials in Turkey (Türkiye)

About this study

Official title: Evaluation of the Effect of Elimination Diet on Intestinal Mucus Barrier in Infants Diagnosed With Cow's Milk Protein Allergy

The goal of this observational study is to learn about the effects of cow's milk protein elimination diets on breastfed infants under 26 weeks of age with newly diagnosed non-IgE-mediated CMPA. The main question it aims to answer is:

Does a cow's milk protein elimination diet improve clinical symptoms (CoMiSS scores), growth parameters, and gut immune markers (MUC2 and sIgA) in breastfed infants with CMPA?

Participants included breastfed infants under 26 weeks diagnosed with non-IgE-mediated CMPA and healthy age- and sex-matched controls without allergies. Infants and their mothers were followed prospectively. Data were collected at baseline and at the end of the study through face-to-face surveys with mothers, three-day food records, anthropometric measurements, CoMiSS evaluations, and stool samples. Mothers in the CMPA group received education on elimination diets, calcium supplementation, and complementary feeding guidance, while the control group received only complementary feeding guidance. Stool samples were analyzed for MUC2 and sIgA using ELISA.

Read the detailed description

The study included breastfed babies under 26 weeks of age who were diagnosed with new non-IgE-mediated CMPA by an allergist, had an elimination diet, and applied to two hospitals designated in Türkiye. Infants and their mothers without allergies or atopic diseases, similar in age and gender, were in the control group. According to the power analysis performed with G*Power, a total of 32 infants were needed to detect a medium-sized difference with a 5% type I error rate and 85% power. The study began with 20 infants with CMPA and 18 healthy infants. Following dietary noncompliance and withdrawals, the study concluded with 17 infants in each group.

Data were collected at two time points: the beginning and end of the study. At each point, face-to-face surveys were administered to mothers, three-day food records were obtained for both mothers and infants, and infants' anthropometric measurements, Cow's Milk Protein-related Symptom Scores (CoMiSS), and stool samples were collected.

Mothers in the case group received detailed training on cow's milk protein (CMP) elimination diets and complementary feeding and were supplemented with 1000 mg/day of calcium. The control group received only complementary feeding guidance. Monthly follow-ups were conducted to monitor compliance. The elimination diet in the case group was prescribed and supervised by a dietitian, with reintroduction following the "milk ladder" protocol after an average of 1.9±0.79 months. In the control group, final assessments were performed three months after baseline. At study completion, all initial measurements were repeated, and a second stool sample was collected.

Infants' body weight (kg), length (cm) and head circumference (cm) measurements were taken by a physician using a standardized scale, infantometer and non-stretch tape measure, in accordance with the method recommended by the World Health Organisation. Anthropometric measurements [length-for-age (LFA), weight-for-age (WFA), weight-for-length (WFL) and head circumference-for-age (HCFA)] were assessed using the WHO ANTHRO Software according to Z-scores (z-score=patient's value-mean value/standard deviation).

Three-day food records (two weekdays, one weekend day) were collected from mothers and infants. Mothers' records were used to assess adherence to the elimination diet, and participants consuming dairy during the diet were excluded. Portion sizes were estimated using a portion size picture book. Daily energy and nutrient intakes were analyzed using BeBiS software (version 9.0). Infants' intakes were evaluated against Adequate Intake (AI) reference values from the Dietary Reference Intakes (DRI). Breast milk intake was estimated using the ALSPAC method: 100 mL for feeds >10 minutes and 50 mL for feeds <5 minutes, with reference values of 780 mL/day for 0-6 months and 600 mL/day for 7-12 months.

The clinical symptoms of infants were assessed using CoMiSS. CoMiSS is a scoring system that assesses crying, regurgitation, stool type (Bristol stool scale), skin and respiratory symptoms, with a total score ranging from 0 to 33.

Stool samples were collected in a container with a spoon at the beginning and end of the study to ensure an adequate quantity (≥50 mg) was obtained. The samples were stored at -80°C to prevent loss of bioactivity and contamination. MUC2 and sIgA analyses were performed using the sandwich enzyme immunoassay method with Human MUC2 and Human sIgA ELISA kits via the enzyme-linked immunosorbent assay (ELISA) method. The Human MUC2 ELISA kit has a sensitivity of 0.57 ng/mL and a measurement range of 1.57-100 ng/mL. The Human sIgA ELISA kit has a sensitivity of 0.098 µg/mL and a measurement range of 0.312-20 µg/mL. According to the analysis protocol, samples and standards were added in duplicate to microtiter wells. Then, biotin-conjugated specific antibody and avidin-HRP conjugate were applied. After the color developed with the TMB substrate, the reaction was stopped with a stop solution containing sulfuric acid. Absorbance was measured at a wavelength of 450±10 nm. Concentrations were then calculated using a standard curve based on the obtained optical density values.

Keywords
Cow Milk Protein Allergy, Mucin-2, Secretory Immunoglobulin A, Elimination Diet
Medical subject headings
Medullary cystic kidney disease 1

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. MUC2 level

    Measured: From the day of CMPA diagnosis in infants until three months later in case group From the beginning the study in infants until three months later in control group

  2. sIgA level

    Measured: From the day of CMPA diagnosis in infants until three months later in case group From the beginning the study in infants until three months later in control group

Secondary outcomes (1)
  1. Monitoring of growth

    Measured: From the day of CMPA diagnosis in infants until three months later in case group From the beginning the study in infants until three months later in control group

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Nov 2025
  2. Study start4 Sep 2023
  3. Primary completion4 Oct 2023
  4. Study completion30 Aug 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
34 participants (actual)
Target duration
3 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT07242950
Sponsor's protocol ID
KA23/257
Status last verified
Nov 2025
First submitted
19 Sep 2025
Last updated
21 Nov 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data obtained through this study may be provided to qualified researchers with academic interest on CMPA. Data or samples shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e. a material transfer agreement) are prerequisites to the sharing of data with the requesting party.

Questions about this trial

What is this clinical trial studying?

An observational study of Cow Milk Protein Allergy and Mucin, run by Baskent University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 17 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

MUC2 level (time frame: From the day of CMPA diagnosis in infants until three months later in case group From the beginning the study in infants until three months later in control group). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in